Part One: Membrane Protein Targets and Targeting
As the pharmaceutical and biotech industries shift their attentions from small molecule therapeutics to biologics, an increased amount of attention is being paid to the prospect of membrane proteinsas drug targets for antibodies and other protein scaffolds. For these large target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecules and the potential for using antibodies for the targeted delivery of therapeutics. However, for the field to advance, fundamental challenges of antigen quality, screening methodology, antibody engineering and target identification must be resolved.
This two-part meeting provides a forum in which discovery biologists and protein engineers can come together to discuss next generation strategies and technologies that will allow antibody-and alternate scaffold-based therapeutics directed against these target families to advance into the clinic and beyond.
The first meeting in the set, Membrane Protein Targets and Targeting, will discuss the fundamental challenges associated with targeting specific membrane protein families, and provide updates of the application of nanobodies and other small protein scaffolds to optimize binding. The conference also explores novel approaches to targeting and signaling across membrane barriers.
Topics may include, but are not limited to:
Biology of GPCR Targets:
• What specific GPCRs are the most druggable (and why)?
• Selection criteria for membrane proteins appropriate for antibody targeting
• Research models for development of antibodies against GPCR targets
• Signaling mechanisms for GPCRs and their ligands
• Biased GPCR signaling
• Species cross reactivity issues
• Clinical perspective on receptor occupancy and activity
• Case studies of GPCR-based antibody therapeutics in preclinical or clinical development
Biology of Ion Channel Targets:
• Pharmacologically active ion channels and families druggable as potential antibody therapeutics
• Functional screening for ion channel targets
• Strategies for ion channel targeting
• Accessing CNS channels
• Targeting ion channels with alternative scaffolds (camelid, shark, bovine, darpins, fibronectins, rabbits, etc.
• New ion channel structures determined by electron microscopy
• Case studies of ion channel-based antibody therapeutics in preclinical or clinical development
Other Membrane Protein Targets:
• Bacterial surface antigens
• Other multi-pass proteins and cell surface antigens
• Emerging strategies for getting past the membrane barrier
Who should attend:Directors, Managers, Researchers, and Scientists from Pharmaceutical and Biotech Companies, Academic/Government research labs working in the fields of Antibody Discovery, Antibody and Protein Engineering, Biophysical Characterization, Candidate Screening, Discovery Biology, Protein Biochemistry, Structural Biology and Target Identification & Validation
If you are interested in speaking, please click here to submit a proposal.
The deadline for submission is March 28, 2014.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact:
Cambridge Healthtech Institute
T: (+1) 207-869-9199
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483